Abstract 3581
Background
The incidence of infections is poorly studied in patients (pts) with neuroendocrine (NET) tumors treated with everolimus (eve) outside of clinical trials. We aimed to evaluate the incidence and risk factors for opportunistic infections (OpI) or any serious infection among eligible pts.
Methods
Retrospective multicenter Latin American cohort of consecutive pts with advanced NET who received at least one dose of eve. Duration of eve, comorbidities, organ dysfunctions, institution, type of prior treatment and concurrent immunosuppressive condition were tested for possible associations with serious (grade 3-5) infections in univariate and multivariable logistic regression models.
Results
111 pts from 5 centers were included: most were men (57.7%) and had pancreatic NET (49.5%). The median duration of eve treatment was 8.9 months and 30 (27%) pts required a dose reduction of eve due to any toxicity. The median overall survival of pts was 54.3 months. In a median follow-up of 32.9 months, 34 (30.6%) pts experienced infections of any grade, 24 (21.6%, 95% confidence interval [CI]: 12.9 – 28.5%) pts had a serious infection and 8 (7.2%, 95% CI: 2.6 – 12.6%) had at least one OpI. Among pts with OpI, the pathogens were Candida sp, Toxoplasma gondi, Pneumocystis sp and Cryptococcus sp; the most common serious infections were pneumonia and gastrointestinal infection. Eight pts (7.2%) died and all deaths were deemed as related to eve. The multivariable analysis identified eve duration (every 6-month increase; Odds Ratio [OR]: 1.26, 95%CI: 1.02-1.55; p = 0.04) and Charlson comorbidity score (OR: 1.47, 95% CI: 1.03-2.08; p = 0.03) as independent risk factors for serious infection.
Conclusions
Infections are more frequent in NET pts using eve than previously reported by clinical trials - 2% had serious infections in the RADIANT-3 trial. Pts on eve should be closely monitored for infections, especially those receiving eve for several months.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Rachel Riechelmann.
Funding
Has not received any funding.
Disclosure
J.M. O’Connor: Honoraria (self): Novartis. R.P. Riechelmann: Honoraria (self): Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
3608 - Prognostic impact of Body Mass Index (BMI) on overall survival in patients with metastatic breast cancer
Presenter: Khalil SALEH
Session: Poster Display session 2
Resources:
Abstract
2686 - Clinicopathological characteristics, survival and prognostic factors of breast cancer-related microangiopathic haemolytic anemia: a multicenter study
Presenter: Marion Alhenc Gelas
Session: Poster Display session 2
Resources:
Abstract
1565 - Metabolic tumor volume by 18F-FDG PET/CT is an independent prognostic factor in metastatic breast cancer
Presenter: Heekyung Ahn
Session: Poster Display session 2
Resources:
Abstract
4498 - Patient Preferences for breast cancer treatments: A Discrete Choice Experiment from four European countries
Presenter: Thomais Konstantopoulou
Session: Poster Display session 2
Resources:
Abstract
1423 - Palbociclib plus fulvestrant as second- or later-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study
Presenter: Diana Lüftner
Session: Poster Display session 2
Resources:
Abstract
2284 - Ventriculoperitoneal Shunt for CNS Metastasis in Breast Cancer: Clinical Outcomes Based on Intrinsic Subtype
Presenter: Hee Kyung Kim
Session: Poster Display session 2
Resources:
Abstract
4598 - Administration of chemotherapy for metastatic breast cancer near the end of life: a population registry study
Presenter: Luisa Edman Kessler
Session: Poster Display session 2
Resources:
Abstract
5706 - Prognostic value of histological growth pattern in patients operated for breast cancer liver metastases
Presenter: Ali Bohlok
Session: Poster Display session 2
Resources:
Abstract
1697 - Illness perceptions, quality of life and mood in metastatic breast cancer patients
Presenter: Isabel Domingues
Session: Poster Display session 2
Resources:
Abstract
1935 - Multidisciplinary Treatments Increases Overall Survival in Patients with Newly Diagnosed Stage IV Breast Cancer:An Analysis of 2010–2014 SEER Data
Presenter: Jian Zhang
Session: Poster Display session 2
Resources:
Abstract